Preliminary results indicate that the benefit of changing to an induction-concurrent sequence remains uncertain ; replacing fluorouracil with oral capecitabine warrants further validation in view of its convenience , favorable toxicity profile , and favorable trends in efficacy ; and accelerated fractionation is not recommended for patients with locoregionally advanced NPC who receive chemoradiotherapy .